Diagnosing cancers of unknown primaries
Friday, 27 February, 2009
A diagnostic test for cancers of unknown primaries developed by scientists from the Peter MacCallum Cancer Centre will be commercialised by Melbourne biotech Circadian Technologies and pathology provider Healthscope.
The diagnostic methodology, co-invented by Peter Mac’s Professor David Bowtell, will be further developed and clinically validated by Clinical Laboratories, a subsidiary of Healthscope.
The test is based comparing the pattern of gene expression of cancers of unknown primaries with a database of known tumours.
Marketing in Australia, New Zealand, Malaysia and Singapore will be handled by Healthscope, while Circadian has rights to the rest of the world.
For more information, see the March/April issue of Australian Life Scientist.
Placebo pain relief works differently across the human body
Researchers have used placebo pain relief to uncover a map-like system in the brainstem that...
COVID infection ages blood vessels, particularly in women
Blood vessels gradually become stiffer with age, but a new study by international researchers...
Lead exposure linked to memory problems, even decades later
Historic lead levels from the era of leaded petrol may be contributing to cognitive issues 50...
